- Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Ruth Plummer et al, 2007, Clinical Cancer Research CrossRef - Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
null Wajant, 2019, Cancers CrossRef - Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications
Elisabeth G.E. de Vries et al, 2006, Clinical Cancer Research CrossRef - Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner
Xiu-Xian Wu et al, 2009, Clinical Cancer Research CrossRef - Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
Karthikeyan Kandasamy et al, 2008, Molecular Cancer Therapeutics CrossRef - Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
Stephan Macher-Goeppinger et al, 2009, Clinical Cancer Research CrossRef - Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Prostate Cancer Cells
Xiaoping Zhang et al, 2007, Clinical Cancer Research CrossRef - Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
null Lim et al, 2019, Cancers CrossRef - Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
Chunjing Wu et al, 2021, International Journal of Molecular Sciences CrossRef